Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-6

IL-6

Brief Information

Name:Interleukin-6
Target Synonym:CTL Differentiation Factor,Interleukin 6 (Interferon, Beta 2),HSF,B-cell stimulatory factor 2,Interferon beta-2,IL6,IFNB2,IL-6,Interleukin-6,Interleukin 6,Hybridoma Growth Factor,IFN-Beta-2,BSF-2,CDF,B-Cell Differentiation Factor,Interferon, Beta 2,Interleukin BSF-2,BSF2,HGF
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:18
Lastest Research Phase:Approved

Licensing

Project item Indications Research phase Cooperation demands
NSS-21001 Cancer cachexia Preclinical candidate compound identified License-out or co-development.

Product ListCompare or Buy

Part of Bioactivity data

IL6-H8218-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).

IL6-H4218-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

ActiveMax® Human IL-6, Tag Free (Cat. No. IL6-H4218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2856-0.3636 ng/mL (Routinely tested).

IL6-H8218-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

IL6-H4218-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human IL-6 R alpha, Fc Tag (Cat. No. ILR-H5259) on Protein A Biosensor, can bind ActiveMax® Human IL-6, Tag Free(Cat. No. IL6-H4218) with an affinity constant of 35.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

IL6,Interleukin-6,BSF2,HSF,IFNB2

Background

Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and  IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells,et.al. to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor  and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Siltuximab cCLB-8; CNTO-328 Approved Johnson & Johnson Sylvant Mainland China Multicentric Castleman's Disease (MCD) Beigene (Beijing) Biotechnology Co Ltd 2014-04-23 Lung Diseases; Lung Neoplasms; Lymphoma, Non-Hodgkin; Castleman Disease; Colorectal Neoplasms; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Monoclonal Gammopathy of Undetermined Significance; Respiratory Distress Syndrome, Adult; Respiratory Tract Infections; Multiple Myeloma; Pancreatic Neoplasms; Myelodysplastic Syndromes; Smoldering Multiple Myeloma; Carcinoma, Renal Cell; Pneumonia; Head and Neck Neoplasms; Ovarian Neoplasms Details
Thalidomide NSC-66847; NSC-527179; K-17; VP-02 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Japan Leprosy, Lepromatous Fujimoto Pharmaceutical 1982-01-01 HIV Infections; Spondylitis, Ankylosing; Myelodysplastic Syndromes; Idiopathic Pulmonary Fibrosis; Multiple Myeloma; HIV Wasting Syndrome; Erythema Nodosum; Leprosy, Lepromatous; Carcinoma, Hepatocellular Details
Pomalidomide IMID-4047; CDC-394; CC-4047; IMiD-1 Approved Celgene Corp Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 Mainland China Multiple Myeloma Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2013-02-08 Sarcoma; Anemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Sarcoma, Kaposi; Lymphoma, Non-Hodgkin; Amyloidosis; Primary Myelofibrosis; Lymphoma, Follicular; Prostatic Neoplasms; Medulloblastoma; Central Nervous System Neoplasms; Lung Diseases, Interstitial; Multiple Myeloma; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Solid tumours; Lymphoma, B-Cell; Bone Marrow Neoplasms Details
Luminol sodium MP-1032 Approved Selvim, Metrio Psoriasis; Immune System Diseases null 1997-01-01 Coronavirus Disease 2019 (COVID-19); Immune System Diseases; Psoriasis Details
Lenalidomide IMID-5013; CDC-5013; CDC-501; CC-5013; IMiD-3; ENMD-0997 Approved Celgene Corp Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo EU Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular Celgene Europe Bv 2005-12-27 Lymphoma, Follicular; Complex Regional Pain Syndromes; Crohn Disease; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Waldenstrom Macroglobulinemia; Thrombocytopenia; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Radiculopathy; Reflex Sympathetic Dystrophy; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Smoldering Multiple Myeloma; Lymphoma, Large B-Cell, Diffuse; Blood Protein Disorders; Leukemia-Lymphoma, Adult T-Cell; Myelodysplastic Syndromes; Paraproteinemias; Anemia; HIV Infections; Lymphoma, B-Cell; Solid tumours; Lymphoma, T-Cell, Peripheral; Hematologic Diseases; Leukemia, Myeloid Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MEDI-5117 WBP-216; MEDI-5117 Phase 1 Clinical Wuxi Apptec Co Ltd, Medimmune Arthritis, Rheumatoid Details
Cis-urocanic acid Cis-UCA; UCA-001; UCA-002 Phase 2 Clinical Herantis Pharma Dry Eye Syndromes; Urinary Bladder Neoplasms; Xerophthalmia; Dermatitis, Atopic Details
Monoclonal Antibody (Mab) sB24M Phase 1 Clinical Pyoderma Gangrenosum Details
HL-2351 GX-P4; HL-2351; rhIL-1Ra-hyFc Phase 1 Clinical Genexine Inc Arthritis, Rheumatoid; Cryopyrin-Associated Periodic Syndromes Details
FB-704A FB-704; FB-704A Phase 2 Clinical Fountain Biopharma Arthritis, Rheumatoid; Asthma Details
Tocilizumab biosimilar (Mycenax Biotech) Phase 1 Clinical Mycenax Biotech Inc Arthritis, Rheumatoid Details
Ensereptide PXL-01 Phase 3 Clinical Promore Pharma Tissue Adhesions; Post-surgical adhesions; Cicatrix Details
EBI-031 EBI-031 Phase 1 Clinical Sesen Bio Diabetic macular oedema; Uveitis Details
Anti-interleukin-6 receptor monoclonal antibody (Biocad) Phase 2 Clinical Biocad Autoimmune Diseases Details
PF-04236921 PF-4236921; PF-04236921 Phase 2 Clinical Pfizer Pharmaceuticals Ltd (China) Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Crohn Disease Details
Clazakizumab ALD-518; ALD518-003; BMS-645429; BMS-945429 Phase 3 Clinical Alder Biopharmaceuticals Anemia; Graft vs Host Disease; Arthritis, Rheumatoid; Fatigue; Rejection of organ transplantation; Arthritis, Psoriatic; Inflammation; Cachexia; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Stomatitis Details
Wogonin Phase 1 Clinical Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University Respiratory Tract Infections; Neoplasms Details
Gerilimzumab GB-224; RYI-008; ARGX-109 Phase 2 Clinical Argenx Se Arthritis, Rheumatoid Details
Isomyosamine MYMD-1 Phase 2 Clinical Mymd Pharmaceuticals Inc Hashimoto Disease; Healthy Aging Details
Sirukumab BA-003; CNTO-136 Phase 2 Clinical Glaxosmithkline Plc, Janssen Global Services Llc Giant Cell Arteritis; Depressive Disorder, Major; Arthritis, Rheumatoid; Lupus Erythematosus, Cutaneous; Coronavirus Disease 2019 (COVID-19); Polymyalgia Rheumatica; Lupus Nephritis; Lupus Erythematosus, Systemic; Asthma Details
Olokizumab CDP-6038; Anti-IL6-UCB Phase 3 Clinical Ucb Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Arthritis; Crohn Disease Details
Efprezimod alfa CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 Phase 3 Clinical Oncoimmune Leukemia; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Leukemia, Myeloid, Acute; Melanoma Details
Ziltivekimab COR-001 Phase 3 Clinical Astrazeneca Pharmaceutical Co Ltd Anemia; Cardiovascular Diseases; Renal Insufficiency, Chronic; Inflammation Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message